Buparlisib Completed Phase 2 Trials for Chronic Lymphocytic Leukemia Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT02340780Buparlisib in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia